deferoxamine has been researched along with isoniazid in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (15.63) | 18.7374 |
| 1990's | 12 (37.50) | 18.2507 |
| 2000's | 10 (31.25) | 29.6817 |
| 2010's | 5 (15.63) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Hoy, T; Humphrys, J; Jacobs, A; Ponka, P; Williams, A | 1 |
| Campbell, RA; Gale, GR; Jones, MM; Litchenberg, WH; Singh, PK; Smith, AB | 1 |
| Eisenstein, RS; Garcia-Mayol, D; Munro, HN; Pettingell, W | 1 |
| Baker, E; Richardson, DR | 1 |
| Fisher, EA; Kruck, TP; McLachlan, DR | 1 |
| Finch, CA; Huebers, HA; Kim, BK | 1 |
| Baker, E; Vitolo, ML; Webb, J | 1 |
| Bottomley, SS | 1 |
| Finch, CA; Johnson, DK; Pippard, MJ | 1 |
| Ponka, P; Richardson, DR; Tran, EH | 1 |
| Ponka, P; Richardson, DR | 1 |
| Crowe, A; Morgan, EH | 1 |
| Cabantchik, ZI; Loyevsky, M; Ponka, P; Tsafack, A | 1 |
| Bhattacharya, M; Chemtob, S; Hanna, N; Hardy, P; Lachapelle, P; Ponka, P; Varma, DR | 1 |
| Milnes, K; Richardson, DR | 1 |
| Darnell, G; Richardson, DR | 1 |
| Cabantchik, ZI; Glickstein, H; Konijn, AM; Meyron-Holtz, EG; Slotki, IN; Vaisman, B | 1 |
| Franklin Bunn, H; Horiguchi, H | 1 |
| Gao, J; Richardson, DR | 1 |
| Antholine, WE; Chitambar, CR; Green, DA; Richardson, DR; Wong, SJ | 1 |
| Breuer, W; Cabantchik, ZI; Hershko, C; Konijn, AM; Link, G; Ponka, P | 1 |
| Chaston, TB; Lovejoy, DB; Richardson, DR; Watts, RN | 1 |
| Richardson, DR | 1 |
| Le, NT; Richardson, DR | 1 |
| Cabantchik, ZI; Hershko, CM; Konijn, AM; Link, GM | 1 |
| Bast, A; den Hartog, GJ; Kaiserová, H; Kvasnicková, E; Schröterová, L; Simůnek, T | 1 |
| Fu, D; Nurtjahja-Tjendraputra, E; Phang, JM; Richardson, DR | 1 |
| Kovacevic, Z; Richardson, DR; Yu, Y | 1 |
3 review(s) available for deferoxamine and isoniazid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Sideroblastic anaemia.
Topics: 5-Aminolevulinate Synthetase; Adult; Anemia, Sideroblastic; Blood Transfusion; Bone Marrow; Chloramphenicol; Deferoxamine; Erythroblasts; Ethanol; Female; Ferrochelatase; Heme; Hemochromatosis; Humans; Iron Deficiencies; Isoniazid; Male; Melphalan; Myeloproliferative Disorders; Pyridoxine; Syndrome | 1982 |
Therapeutic potential of iron chelators in cancer therapy.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Deferoxamine; Humans; Iron; Iron Chelating Agents; Isoniazid; Neoplasms; Pyridoxal; Thiosemicarbazones; Tumor Suppressor Protein p53 | 2002 |
29 other study(ies) available for deferoxamine and isoniazid
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Effective iron chelation following oral administration of an isoniazid-pyridoxal hydrazone.
Topics: Animals; Deferoxamine; Heme; Iron; Iron Chelating Agents; Isoniazid; Liver; Male; Pyridoxal; Pyridoxine; Rats; Spleen | 1979 |
Comparative iron mobilizing actions of deferoxamine, 1,2-dimethyl-3-hydroxypyrid-4-one, and pyridoxal isonicotinoyl hydrazone in iron hydroxamate-loaded mice.
Topics: Animals; Deferiprone; Deferoxamine; Hydroxamic Acids; Iron; Isoniazid; Male; Mice; Mice, Inbred Strains; Pyridones; Pyridoxal; Tissue Distribution | 1991 |
Regulation of ferritin and heme oxygenase synthesis in rat fibroblasts by different forms of iron.
Topics: Animals; Cell Line; Deferoxamine; Enzyme Induction; Ferritins; Fibroblasts; Heme; Heme Oxygenase (Decyclizing); Iron; Isoniazid; Kinetics; Pyridoxal; Rats | 1991 |
The release of iron and transferrin from the human melanoma cell.
Topics: Antigens, Neoplasm; Cell Line; Deferoxamine; Humans; Iron; Iron Chelating Agents; Isoniazid; Kinetics; Melanoma; Melanoma-Specific Antigens; Neoplasm Proteins; Pyridoxal; Transferrin | 1991 |
Suppression of deferoxamine mesylate treatment-induced side effects by coadministration of isoniazid in a patient with Alzheimer's disease subject to aluminum removal by ionspecific chelation.
Topics: Aluminum; Alzheimer Disease; Chelation Therapy; Chromatography, High Pressure Liquid; Deferoxamine; Drug Therapy, Combination; Humans; Injections, Intramuscular; Isoniazid; Monoamine Oxidase; Pyridoxine | 1990 |
Effectiveness of oral iron chelators assayed in the rat.
Topics: Administration, Oral; Animals; Deferoxamine; Female; Ferritins; Iron Chelating Agents; Isoniazid; Male; Pyridoxal; Rats; Rats, Inbred Strains | 1987 |
Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture.
Topics: Animals; Cells, Cultured; Chelating Agents; Deferoxamine; Iron; Isoniazid; Liver; Male; Pyridoxal; Rats; Rats, Inbred Strains; Transferrin | 1985 |
A rapid assay for evaluation of iron-chelating agents in rats.
Topics: Animals; Bile; Deferoxamine; Female; Ferritins; Injections, Intravenous; Iron; Iron Chelating Agents; Iron Radioisotopes; Isoniazid; Liver; Male; Pyridoxal; Rats; Rats, Inbred Strains; Time Factors | 1981 |
The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents.
Topics: Antineoplastic Agents; Biological Transport, Active; Cell Division; Deferoxamine; Gallium; Humans; Iron; Iron Chelating Agents; Isoniazid; Pyridoxal; Transferrin; Tumor Cells, Cultured | 1995 |
The iron metabolism of the human neuroblastoma cell: lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis.
Topics: Deferoxamine; DNA; Humans; Iron; Iron Chelating Agents; Isoniazid; Neuroblastoma; Osmolar Concentration; Pyridoxal; Thymidine; Transferrin; Tumor Cells, Cultured | 1994 |
Effects of chelators on iron uptake and release by the brain in the rat.
Topics: 2,2'-Dipyridyl; Aging; Animals; Biological Transport; Bone and Bones; Brain; Deferiprone; Deferoxamine; Female; Iron; Iron Chelating Agents; Iron Radioisotopes; Isoniazid; Kidney; Liver; Male; Pentetic Acid; Pyridones; Pyridoxal; Rats; Rats, Wistar | 1994 |
Mode of action of iron (III) chelators as antimalarials. IV. Potentiation of desferal action by benzoyl and isonicotinoyl hydrazone derivatives.
Topics: Animals; Antimalarials; Deferoxamine; Drug Synergism; Ferric Compounds; Humans; Hydrazones; Iron Chelating Agents; Isoniazid; Kinetics; Naphthols; Plasmodium falciparum; Spectrometry, Fluorescence | 1996 |
Prevention of postasphyxia electroretinal dysfunction with a pyridoxal hydrazone.
Topics: Animals; Animals, Newborn; Asphyxia Neonatorum; Deferoxamine; Disease Models, Animal; Electroretinography; Humans; Hydrogen Peroxide; Infant, Newborn; Iron Chelating Agents; Isoniazid; Malondialdehyde; Oxidative Stress; Peroxides; Pyridoxal; Retina; Swine; Vision Disorders | 1997 |
The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone.
Topics: Antineoplastic Agents; Apoptosis; Benzaldehydes; Cell Cycle; Cell Division; Deferoxamine; DNA Fragmentation; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Ferritins; Growth Inhibitors; HL-60 Cells; Humans; Hydrazones; Iron; Iron Chelating Agents; Isoniazid; Ligands; Molecular Structure; Naphthols; Neoplasm Proteins; Neoplasms; Pyridoxal; Structure-Activity Relationship; Transferrin; Tumor Cells, Cultured | 1997 |
The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation.
Topics: Antineoplastic Agents; Cell Cycle; Cell Division; Chelation Therapy; Deferoxamine; Growth Inhibitors; Iron; Iron Chelating Agents; Isoniazid; Ligands; RNA, Neoplasm; Tumor Cells, Cultured | 1999 |
The cellular labile iron pool and intracellular ferritin in K562 cells.
Topics: Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Iron-Regulatory Proteins; Iron-Sulfur Proteins; Isoniazid; K562 Cells; Kinetics; Lysosomes; Protease Inhibitors; RNA-Binding Proteins; Time Factors | 1999 |
Erythropoietin induction in Hep3B cells is not affected by inhibition of heme biosynthesis.
Topics: Cell Survival; Deferoxamine; Enzyme Inhibitors; Erythropoietin; Heme; Heptanoates; Humans; Isoniazid; Protoporphyrins; Tumor Cells, Cultured | 2000 |
The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression.
Topics: Antineoplastic Agents; Cell Cycle; Cyclins; Deferoxamine; Female; Genes, Retinoblastoma; Humans; Hydroxyurea; Iron; Iron Chelating Agents; Isoniazid; Pyridoxal; Structure-Activity Relationship; Tumor Cells, Cultured | 2001 |
Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: effect on the R2 subunit of ribonucleotide reductase.
Topics: Antineoplastic Agents; Cell Division; Deferoxamine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Hydroxyurea; Iron Chelating Agents; Isoniazid; Mutation; Protein Subunits; Ribonucleotide Reductases; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |
Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells.
Topics: Animals; Animals, Newborn; Blood Transfusion; Cells, Cultured; Deferoxamine; Female; Ferritins; Heart; Iron; Iron Chelating Agents; Iron Radioisotopes; Isoniazid; Kinetics; Pyridoxal; Rats; Rats, Wistar | 2003 |
Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
Topics: Animals; Ascorbic Acid; Blotting, Northern; Blotting, Western; Cell Division; Chelating Agents; Deferoxamine; DNA; Dose-Response Relationship, Drug; Electron Spin Resonance Spectroscopy; Free Radicals; Glutathione; Humans; Iron; Iron Chelating Agents; Isoniazid; Models, Chemical; Oxidation-Reduction; Oxygen; Plasmids; Protein Binding; Pyridines; Rats; Thiosemicarbazones; Time Factors; Tumor Cells, Cultured | 2003 |
Potent iron chelators increase the mRNA levels of the universal cyclin-dependent kinase inhibitor p21(CIP1/WAF1), but paradoxically inhibit its translation: a potential mechanism of cell cycle dysregulation.
Topics: Cell Cycle; Cells, Cultured; Cisplatin; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cysteine Endopeptidases; Dactinomycin; Deferoxamine; DNA Damage; Gene Expression Regulation; Humans; Iron Chelating Agents; Isoniazid; Multienzyme Complexes; Proteasome Endopeptidase Complex; Protein Biosynthesis; Receptors, Transferrin; RNA, Messenger; Tumor Suppressor Protein p53 | 2003 |
Iron chelation therapy.
Topics: Administration, Oral; Benzoates; beta-Thalassemia; Chelation Therapy; Chemical and Drug Induced Liver Injury; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Infusions, Intravenous; Iron Chelating Agents; Iron Overload; Isoniazid; Pyridones; Pyridoxal; Survival; Triazoles | 2005 |
Iron is not involved in oxidative stress-mediated cytotoxicity of doxorubicin and bleomycin.
Topics: Aldehydes; Antibiotics, Antineoplastic; Apoptosis; Bleomycin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deferoxamine; Doxorubicin; Electron Spin Resonance Spectroscopy; Free Radicals; Humans; Hydrazones; Hydrogen Peroxide; Iron; Iron Chelating Agents; Iron Compounds; Isoniazid; Lipid Peroxidation; Lung Neoplasms; Oxidative Stress; Pyridoxal; Razoxane; Time Factors | 2006 |
Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression.
Topics: Anemia, Iron-Deficiency; Animals; Cell Cycle; Cell Line, Tumor; Deferoxamine; G1 Phase; Half-Life; Humans; Iron; Iron Chelating Agents; Isoniazid; Mice; Proteasome Endopeptidase Complex; S Phase; Siderophores; Ubiquitin | 2007 |
Chelators to the rescue: different horses for different courses!
Topics: Aldehydes; Animals; Deferoxamine; Humans; Hydrazones; Iron Chelating Agents; Iron Overload; Isoniazid; Myocardial Reperfusion Injury; Neoplasms; Pyridines; Pyridoxal; Rats; Reactive Oxygen Species; Thiosemicarbazones | 2011 |